AstraZeneca Pharma India has received approval from the Central Drugs Standard Control Organisation to import Durvalumab for sale and distribution. The drug, combined with chemotherapy, treats resectable non-small cell lung cancer without specific genetic mutations. Lung cancer remains a significant cause of mortality in India, highlighting the importance of this development.
Related Posts
Gautam Adani-led Adani Group appoints two US law firms, among world’s largest, to fight SEC allegations
- staff
- January 20, 2025
- 0
The Adani Group has hired US law firms to handle civil and criminal proceedings by the SEC and Eastern District of New York. Charges against […]
Amazon to surpass $13 billion in cumulative e-commerce exports from India by 2024 end
Amazon projects exceeding $13 billion in cumulative e-commerce exports from India by late 2024. With a rising number of sellers and expanding product offerings, the […]
Banner year beckons again for India after $19 billion IPO record
India’s IPO market is booming, exceeding its fundraising record this year. Experts predict the surge will continue into 2025, fueled by strong economic growth and […]